TriLink BioTechnologies said this week that it has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna's freeze-dried in vitro diagnostic PCR kits.

Biofortuna will use the dNTPs for a line of human leukocyte antigen diagnostic kits it is developing for the transplantation, blood grouping, disease identification, and pharmacogenetic markets. The company is targeting its first product for the sequence-specific primer transplantation market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.